Fig 1: LIN28B inhibition sensitizes cells to p53–MDM2 inhibitors.A Relative mRNA level of LIN28B in control (DMSO) and p53–MDM2 inhibitor Nutlin3a, RG7388 (RG, Idasanutlin) treated cells by analyzing the GSE154065 (HCT116) and GSE104917 (NB1691 neuroblastoma) datasets. *p < 0.05, **p < 0.01. B Relative cell viability as determined by CCK8 in ocular melanoma cells treated by various concentrations of Nutlin3a and MI773. C Correlation between relative cell viability and LIN28B protein level in ocular melanoma cells treated by Nutlin3a (22.2 µM). D Correlation between Nutlin3a IC50 and LIN28B protein level in ocular melanoma cells. E Correlation between relative cell viability and LIN28B protein level in ocular melanoma cells treated by MI773 (22.2 µM). F Correlation between MI773 IC50 and LIN28B protein level in ocular melanoma cells treated. G Relative cell viability as determined by CCK8 in ocular melanoma cells treated by various concentrations of Siremadin and Idasanutlin (RG7388). Representative data of three independent experiments (mean ± s.e.m.). H Relative cell viability of control (shCtrl) and knockdown (shLIN28B) LOXI cells treated by various concentrations of Nutlin3a. The IC50 of each group was shown. Representative data of three independent experiments (mean ± s.e.m.). I Schematic diagram of the working model.